Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis : a phase III, randomized, double-blind study
© 2024. The Author(s)..
PURPOSE: To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC).
METHODS: A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC patients. Patients received (2:1) twice-daily oral ibrexafungerp 300 mg or matching placebo for 1 day. The primary endpoint was clinical cure (vulvovaginal signs and symptoms [VSS] score = 0) at test-of-cure (TOC) on day 11 ± 3. The secondary endpoints included mycological eradication, overall response, and clinical improvement (VSS score ≤ 1) at TOC, and vulvovaginal symptom resolution at follow-up on day 25 ± 4.
RESULTS: In total, 360 patients were included in the modified intention-to-treat set (defined as positive Candida cultured and receiving at least one study drug; 239 for ibrexafungerp, 121 for placebo). Compared with placebo, patients receiving ibrexafungerp had a significantly higher proportion of clinical cure (51.0% vs. 25.6%), mycological eradication (55.6% vs. 18.2%), overall response (33.9%, vs. 8.3%) at TOC and complete symptom resolution (74.5% vs. 39.7%, all P < 0.001) at follow-up. Subgroup analysis of clinical cure indicated that patients with C. albicans could benefit from ibrexafungerp over placebo. A similar benefit trend was also observed in those with non-albicans Candida by post-hoc analysis. Further analyses revealed similar efficacy of ibrexafungerp between patients with fluconazole non-susceptible C. albicans and fluconazole susceptible C. albicans regarding clinical cure and mycological eradication. Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mainly mild in severity.
CONCLUSIONS: As a first-in-class antifungal agent, ibrexafungerp demonstrated promising efficacy and favorable safety for VVC treatment in Chinese patients. CHINADRUGTRIALS.ORG.
CN REGISTRY NUMBER: CTR20220918.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Infection - (2024) vom: 03. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Xiaoqian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s15010-024-02233-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37057849X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37057849X | ||
| 003 | DE-627 | ||
| 005 | 20240404000908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240404s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-024-02233-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM37057849X | ||
| 035 | |a (NLM)38568411 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Xiaoqian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis |b a phase III, randomized, double-blind study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC) | ||
| 520 | |a METHODS: A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC patients. Patients received (2:1) twice-daily oral ibrexafungerp 300 mg or matching placebo for 1 day. The primary endpoint was clinical cure (vulvovaginal signs and symptoms [VSS] score = 0) at test-of-cure (TOC) on day 11 ± 3. The secondary endpoints included mycological eradication, overall response, and clinical improvement (VSS score ≤ 1) at TOC, and vulvovaginal symptom resolution at follow-up on day 25 ± 4 | ||
| 520 | |a RESULTS: In total, 360 patients were included in the modified intention-to-treat set (defined as positive Candida cultured and receiving at least one study drug; 239 for ibrexafungerp, 121 for placebo). Compared with placebo, patients receiving ibrexafungerp had a significantly higher proportion of clinical cure (51.0% vs. 25.6%), mycological eradication (55.6% vs. 18.2%), overall response (33.9%, vs. 8.3%) at TOC and complete symptom resolution (74.5% vs. 39.7%, all P < 0.001) at follow-up. Subgroup analysis of clinical cure indicated that patients with C. albicans could benefit from ibrexafungerp over placebo. A similar benefit trend was also observed in those with non-albicans Candida by post-hoc analysis. Further analyses revealed similar efficacy of ibrexafungerp between patients with fluconazole non-susceptible C. albicans and fluconazole susceptible C. albicans regarding clinical cure and mycological eradication. Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mainly mild in severity | ||
| 520 | |a CONCLUSIONS: As a first-in-class antifungal agent, ibrexafungerp demonstrated promising efficacy and favorable safety for VVC treatment in Chinese patients. CHINADRUGTRIALS.ORG | ||
| 520 | |a CN REGISTRY NUMBER: CTR20220918 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antifungal | |
| 650 | 4 | |a Candida | |
| 650 | 4 | |a Ibrexafungerp | |
| 650 | 4 | |a Randomized clinical trial | |
| 650 | 4 | |a Vulvovaginal candidiasis | |
| 700 | 1 | |a Wang, Wenying |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a An, Ruifang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lihong |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jiajing |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Dabao |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Weihua |e verfasserin |4 aut | |
| 700 | 1 | |a Patiman, Mijiti |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Hongjie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Fengxia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Xiaowan |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shijin |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Songling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yingxiong |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Baojin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Bei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chunlian |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Sumin |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Qinping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d 1973 |g (2024) vom: 03. Apr. |w (DE-627)NLM00001740X |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:03 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s15010-024-02233-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 03 |c 04 | ||